Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2022)

Spero Therapeutics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $100000.0 for Q2 2022.

  • For Q2 2022, Other Non-Current Liabilities changed N/A year-over-year to $100000.0; the TTM value through Jun 2022 reached $100000.0, changed N/A, while the annual FY2021 figure was $802000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $100000.0 in Q2 2022 per SPRO's latest filing, down from $802000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $802000.0 in Q4 2021 to a low of $100000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $261700.0, with a median of $223000.0 recorded in 2018.
  • Peak YoY movement for Other Non-Current Liabilities: rose 11.5% in 2018, then decreased 10.31% in 2019.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $223000.0 in 2018, then decreased by 10.31% to $200000.0 in 2019, then changed by 0.0% to $200000.0 in 2020, then surged by 301.0% to $802000.0 in 2021, then tumbled by 87.53% to $100000.0 in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Other Non-Current Liabilities are $100000.0 (Q2 2022), $802000.0 (Q4 2021), and $200000.0 (Q1 2020).